BioInvent Embarks on Intensive Investor Meeting Program in the U.S., Europe, and Israel, and Posts Updated Presentation on Corporate Website

LUND, Sweden, Oct. 17, 2018 /PRNewswire/ --

BioInvent International AB (OMXS: BINV) today announced that in connection with its intensive upcoming investor meeting program it has published the updated corporate presentation on its website.

During the months of October and November, BioInvent's management will conduct investor meetings across the U.S., Europe, and Israel. In addition, BioInvent will host a Key Opinion Leader (KOL) event in New York on November 6. Details of this event, which will be webcast live and archived on BioInvent's website, will be announced shortly. At the KOL event, BioInvent's management and an invited scientific key opinion leader will present the Company's scientific and clinical value drivers to the U.S. investor community. 

About BioInvent

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company's lead program is BI-1206, currently in Phase l/ll for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent's pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.se.

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

For further information, please contact:
Martin Welschof, CEO
+46(0)46-286-85-50
[email protected]

Hans Herklots, LifeSci Advisors
+41-79-598-71-49
hherklots@lifesciadvisors

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46(0)46-286-85-50
www.bioinvent.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download: